Epstein–Barr Virus Positivity as a Biomarker in First-Line Chemoimmunotherapy for Gastric Cancer
Year: 2027
Type: article
Abstract: Purpose Epstein–Barr virus (EBV)-associated gastric cancer (EBVaGC), which is characterized by an inflamed tumor microenvironment, may represent a relevant subgroup in the setting of immune checkpoint inhibitor (ICI)-based therapy. We evaluated whether EBV positivity identifies a distinct subgroup of gastric cancer in patients receiving first-line chemoimmunotherapy and determined its association with programmed death-ligand 1 (PD-L1) expression and microsatellite instability.
Institutions: The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, The Catholic University of Korea St. Vincent's Hospital, The Catholic University of Korea Yeouido St. Mary's Hospital, The Catholic University of Korea Bucheon St. Mary's Hospital, The Catholic University of Korea Uijeongbu St. Mary's Hospital, The Catholic University of Korea Eunpyeong St. Mary's Hospital, The Catholic University of Korea Incheon St. Mary's Hospital, The Catholic University of Korea Daejeon St. Mary's Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7235582098
